Smart drug targets Hard-to-Treat breast cancer
NCT ID NCT04965766
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests a drug called patritumab deruxtecan in people with advanced hormone-receptor-positive breast cancer that has stopped responding to hormone therapy and chemotherapy. The drug is designed to seek out and destroy cancer cells that have a protein called HER3 on their surface. About 139 participants will receive the drug every three weeks. Researchers will track how many patients' tumors shrink and study which patients benefit most.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
patritumab deruxtecan (U3-1402)
What this could lead to
If it works, this could offer a new treatment option for people with advanced breast cancer that has stopped responding to hormone therapy and chemotherapy.
What could go wrong
This is a Phase 2 trial, so it is still early. The drug may not shrink tumors in enough patients, and side effects could be serious. Results may not apply to all breast cancer types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Limoges
RECRUITINGLimoges, 87042, France
Contact
-
Centre Antoine Lacassagne
RECRUITINGNice, 06189, France
Contact
-
Centre Georges François Leclerc
ACTIVE_NOT_RECRUITINGDijon, 21079, France
-
Centre Léon Bérard
RECRUITINGLyon, 69373, France
Contact
-
Gustave Roussy
RECRUITINGVillejuif, 94805, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Tenon
RECRUITINGParis, 75020, France
Contact
-
Institut Claudius Regaud
RECRUITINGToulouse, 31059, France
Contact
-
Institut Curie
RECRUITINGParis, 75005, France
Contact
-
Institut Paoli Calmettes
RECRUITINGMarseille, 13273, France
Contact
-
Institut Régional du Cancer de Montpellier
RECRUITINGMontpellier, 34298, France
Contact
-
Institut de Cancérologie de l'Ouest
RECRUITINGSaint-Herblain, 44805, France
Contact